Trabectedin monotherapy in an immunocompetent OS mouse model increased infiltration of CD8+ T cells into tumors, associated with reduced numbers of TAM, though to a lesser degree than in other cancer models, and the combination of trabectedin with the PD-1 antagonist antibody showed synergism in controlling tumor progression [128]. Here, CD8A is linked to neoplasm.